First National Bank of Omaha Reduces Holdings in Becton Dickinson and Co (NYSE:BDX)
First National Bank of Omaha decreased its position in Becton Dickinson and Co (NYSE:BDX) by 2.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,218 shares of the medical instruments supplier’s stock after selling 632 shares during the period. First National Bank of Omaha’s holdings in Becton Dickinson and were worth $5,620,000 as of its most recent SEC filing.
Several other institutional investors have also recently bought and sold shares of the company. Morgan Stanley boosted its position in Becton Dickinson and by 66.7% in the second quarter. Morgan Stanley now owns 4,887,187 shares of the medical instruments supplier’s stock worth $1,231,621,000 after purchasing an additional 1,955,095 shares during the last quarter. Nuveen Asset Management LLC raised its stake in shares of Becton Dickinson and by 12,995.3% in the second quarter. Nuveen Asset Management LLC now owns 1,429,875 shares of the medical instruments supplier’s stock valued at $360,343,000 after buying an additional 1,418,956 shares during the period. Thoroughbred Financial Services LLC raised its stake in shares of Becton Dickinson and by 25,302.2% in the second quarter. Thoroughbred Financial Services LLC now owns 990,940 shares of the medical instruments supplier’s stock valued at $99,094,000 after buying an additional 987,039 shares during the period. Vanguard Group Inc. raised its stake in shares of Becton Dickinson and by 2.3% in the second quarter. Vanguard Group Inc. now owns 23,018,011 shares of the medical instruments supplier’s stock valued at $5,800,769,000 after buying an additional 520,350 shares during the period. Finally, Stonehage Fleming Financial Services Holdings Ltd bought a new stake in shares of Becton Dickinson and in the second quarter valued at $101,966,000. 84.29% of the stock is owned by institutional investors and hedge funds.
In other Becton Dickinson and news, CEO Vincent A. Forlenza sold 11,532 shares of the company’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $260.38, for a total transaction of $3,002,702.16. Following the completion of the transaction, the chief executive officer now owns 218,671 shares of the company’s stock, valued at approximately $56,937,554.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP James C. Lim sold 9,299 shares of the company’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $263.53, for a total value of $2,450,565.47. Following the transaction, the executive vice president now directly owns 33,041 shares of the company’s stock, valued at approximately $8,707,294.73. The disclosure for this sale can be found here. Insiders have sold a total of 32,174 shares of company stock valued at $8,354,013 in the last ninety days. 0.12% of the stock is currently owned by corporate insiders.
BDX stock traded up $0.06 during trading on Friday, hitting $244.64. 961,860 shares of the company traded hands, compared to its average volume of 1,180,223. The firm has a market capitalization of $66.59 billion, a PE ratio of 20.94, a P/E/G ratio of 1.62 and a beta of 1.09. Becton Dickinson and Co has a 1 year low of $208.62 and a 1 year high of $264.74. The company has a 50-day moving average of $252.19 and a 200-day moving average of $246.80. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.67 and a current ratio of 1.19.
Becton Dickinson and (NYSE:BDX) last issued its earnings results on Tuesday, November 5th. The medical instruments supplier reported $3.31 earnings per share for the quarter, beating the consensus estimate of $3.30 by $0.01. The company had revenue of $4.58 billion during the quarter, compared to analysts’ expectations of $4.57 billion. Becton Dickinson and had a return on equity of 15.51% and a net margin of 6.84%. Becton Dickinson and’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same period in the prior year, the business posted $2.93 EPS. Sell-side analysts expect that Becton Dickinson and Co will post 12.58 EPS for the current year.
Becton Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Further Reading: Determine Your Level of Risk Tolerance
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.